The Efficacy and Safety of Losartan/Hydrochlorothiazide Combination Drug (Preminent) in Patients With Morning Hypertension.

Trial Profile

The Efficacy and Safety of Losartan/Hydrochlorothiazide Combination Drug (Preminent) in Patients With Morning Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Losartan/hydrochlorothiazide (Primary) ; Losartan
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms MAPPY
  • Most Recent Events

    • 29 Sep 2016 Results of subanalysis (safety and efficacy in very elderly patients) presented at the 26th Scientific Meeting of the International Society of Hypertension
    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
    • 01 Jul 2012 Primary endpoints 'Morning-blood-pressure' and 'Target-achievement-rate' have been met according to results published in Hypertension Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top